Septerna

Septerna

Biotechnology

South San Francisco, California 5,257 followers

Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.

About us

Septerna is on a mission to make the promise of future GPCR medicines a reality for patients. Combining the latest advances in biochemical, structural and computational drug discovery approaches, we have built an industrialized platform to precisely control and modulate GPCR biology and pharmacology to discover and develop new high-impact medicines. With our Native Complex Platform™, we are opening a new frontier in GPCR small molecule discovery technologies to expand the druggable GPCR landscape. We are always looking for talented scientists, drug hunters, and business professionals to join our mission to launch a new era of GPCR medicines. If you’re passionate about innovation, energized by teamwork, and fueled by the desire to change patient lives, join us and become a part of the Septerna story!

Industry
Biotechnology
Company size
51-200 employees
Headquarters
South San Francisco, California
Type
Privately Held

Locations

  • Primary

    250 E Grand Ave

    65

    South San Francisco, California 94080, US

    Get directions

Employees at Septerna

Updates

  • View organization page for Septerna, graphic

    5,257 followers

    Thank you, Nasdaq, for the incredible opportunity to ring the Opening Bell! It was an unforgettable moment to celebrate Septerna’s IPO thanks to our dedicated team, investors, and supporters. This milestone marks the beginning of an exciting new chapter as we work to unlock the potential of GPCR-targeted therapies and transform patient care. We’re proud to join the NASDAQ family as $SEPN! #Biotech #NASDAQListed

    View organization page for Nasdaq, graphic

    500,913 followers

    💫 Their mission: to pioneer a new era of G protein coupled receptors. 🔬 Septerna is unlocking the therapeutic potential of GPCRs to address unmet patient needs. 🔔 It’s an honor to celebrate with you as you join the #NasdaqListed family, $SEPN!

    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for Septerna, graphic

    5,257 followers

    What a monumental day for Septerna! We rang the Nasdaq Opening Bell today in celebration of our #IPO and the start of an exciting new chapter. With our public listing as $SEPN, we’re well positioned to accelerate the development of our GPCR-targeted therapies. This achievement wouldn’t have been possible without the hard work of our talented team, the support of our broad network of partners, and the trust of our investors. Together, we’re dedicated to bringing future medicines to patients! #NASDAQ #OpeningBell #GoingPublic #Biotech #Innovation

    • No alternative text description for this image
    • No alternative text description for this image
  • View organization page for Septerna, graphic

    5,257 followers

    At the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2024 this weekend, we shared some exciting data supporting clinical development for our oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist program. SEP-786, our lead candidate, is currently being evaluated in a Phase 1 clinical trial for the treatment of hypoparathyroidism. The data presented also highlights and reaffirms the unique ability of our Native Complex  Platform™ to successfully target GPCRs and create potential therapies for difficult to treat diseases. Read more: https://lnkd.in/g8W2CWDa View the poster: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://lnkd.in/g3vWZY_E #ASBMR 2024

    • No alternative text description for this image
  • View organization page for Septerna, graphic

    5,257 followers

    We are thrilled to welcome to our team Jae Kim, M.D., FACC, as Chief Medical Officer; Monica Gangal as Vice President of Clinical Operations; and Matthew Holdren, Ph.D., DABT, as Vice President of Toxicology! These accomplished executives bring strong individual and combined experience in both biotech and pharma organizations that will be key to Septerna as we transition into a clinical stage organization. Welcome to the team! Read more at: https://lnkd.in/gswwxQp4

    • No alternative text description for this image
  • View organization page for Septerna, graphic

    5,257 followers

    July is #GravesDiseaseAwarenessMonth. People living with Graves' disease face difficult choices with current treatments, often having to sacrifice one health goal for another. Patients choosing surgery for remission must rely on lifelong thyroid supplementation, while those opting for radiation risk developing or worsening of ophthalmopathy. Antithyroid drugs are often the best option, but are associated with a high rate of relapse. There is an urgent need for better treatment options that can address the challenges effectively. At Septerna, we are committed to providing hope for new therapeutic options that can help patients meet their treatment goals. Learn more: https://bit.ly/4eVjEbc #drugdiscovery

    • No alternative text description for this image
  • View organization page for Septerna, graphic

    5,257 followers

    Pride Month is a time to honor the past, celebrate progress, and advocate for a more inclusive world.  At Septerna, we are committed to inclusion and equity for our talented LGBTQ+ employees and to developing therapies that improve patients' lives, many of whom are part of the LGBTQ+ community. We marked the month with educational and celebratory events to foster understanding and promote allyship, and we look forward to joining Gay for Good San Francisco for this weekend’s Pink Triangle Take-Down event following the San Francisco Pride Parade.  Happy Pride Month from all of us at Septerna! #PrideMonth #Inclusion #LGBTQ+ #Pride2024 

  • View organization page for Septerna, graphic

    5,257 followers

    We are pleased to welcome our wonderful group of Summer interns, who will be working with us in medicinal chemistry, people and culture, protein science and platform technology. We look forward to seeing the valuable contributions they will make to our team.

    • No alternative text description for this image
  • View organization page for Septerna, graphic

    5,257 followers

    Our CEO Jeff Finer comments on the preclinical data we presented this week at #ENDO2024. Our PTH1R agonist is the only small molecule in development to behave similarly to native PTH, and we are excited about its potential to reshape the treatment paradigm for hypoparathyroidism.   We are also pleased to showcase data from our TSHR antagonist program demonstrating its ability to target the known drivers of Graves’ disease, an indication for which there are currently no disease-modifying oral small molecules. Learn more: https://bit.ly/3yLu7p4

    • No alternative text description for this image

Similar pages

Browse jobs

Funding